
The next-generation KRAS G12C inhibitor MK-1084 showed promising efficacy and safety as a single agent and in combinations for advanced colorectal cancer.

The next-generation KRAS G12C inhibitor MK-1084 showed promising efficacy and safety as a single agent and in combinations for advanced colorectal cancer.

DNA methylation, RTK pathway changes, and KRAS amplifications may drive resistance to sotorasib plus panitumumab in KRAS G12C colorectal cancer.

Escalated adjuvant chemotherapy, guided by ctDNA, did not improve recurrence-free survival for stage III colon cancer patients, per DYNAMIC-III trial.

Sara M. Tolaney, MD, MPH, shares new data from the ASCENT-04 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer.

Nivolumab plus ipilimumab shows durable survival benefit over chemotherapy and monotherapy in mismatch repair-deficient colorectal cancer.

Anlotinib plus chemotherapy has emerged as a first-line alternative to bevacizumab/chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer.

The BREAKWATER trial showed encorafenib, cetuximab, & mFOLFOX6 significantly improved PFS and OS in first-line BRAF V600E-mutant mCRC.

A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy, improving survival without disease progression.

Vepdegestrant significantly improved progression-free survival vs fulvestrant in pretreated ESR1-mutant, ER-positiver, HER2-negative advanced breast cancer.

T-DXd significantly improved overall survival vs ramucirumab/paclitaxel in second-line HER2-positive unresectable/metastatic gastric/GEJ cancer.

Sacituzumab govitecan & pembrolizumab significantly improved PFS in PD-L1+ advanced TNBC vs. chemo/pembrolizumab in the ASCENT-04 study.

Terence M. Williams, MD, PhD, discussed the phase 1 DINOMITE trial of radiation therapy and papaverine in rectal cancer at City of Hope.

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with the agency.

Sara M. Tolaney, MD, MPH, highlights a transformative year for breast cancer research at this year’s ASCO Annual Meeting.

The pivotal AMPLIFY trial aims to support FDA approval of ⁶⁴Cu-SAR-bisPSMA as a best-in-class imaging tool in prostate cancer.

EBC-129 has been granted FDA fast track designation for the treatment of pancreatic ductal adenocarcinoma, paving the way for development of this antibody-drug conjugate.

Terence M. Williams, MD, PhD, discusses what inspired the new phase 1 DINOMITE trial at City of Hope.

A phase 1b trial plans to evaluate AKY-1189 for the treatment of Nectin-4–expressing tumors.

Toon Van Gorp, MD, PhD, discusses the rationale behind and the findings from the phase 3 MIRASOL trial of mirvetuximab soravtansine in patients with folate receptor α–positive, platinum-resistant ovarian cancer.


This priority review designation for sevabertinib in previously treated HER2-mutant non–small cell lung cancer is supported by data from the phase 1/2 SOHO-01 study.

A zanubrutinib, venetoclax, and obinutuzumab triplet achieved deep remissions and high undetectable measurable residual disease rates in relapsed CLL.

Alexander Kenigsberg, MD, discusses a new option for treating prostate cancer: robotic high-intensity focused ultrasound.

The EFTISARC-NEO trial of eftilagimod alfa with radiotherapy and pembrolizumab in resectable soft tissue sarcoma achieved its primary end point.

Nini Wu, MD, MBA, highlights key tactics that community oncology practices can implement now to better support their clinicians and staff.

START and OneOncology launch 3 new early-phase trial sites, expanding access to new cancer research in community oncology settings.

Nini Wu, MD, MBA, discusses long-term investments aimed at stabilizing and strengthening the future of community oncology

In ASCENT-03, sacituzumab govitecan significantly extended progression-free survival in metastatic triple-negative breast cancer not eligible for PD-(L)1 inhibitors.

The FDA cleared an investigational new drug application for AVZO-1418/DB-1418, and a phase 1/2 trial in advanced solid tumors will begin later this year.

POLB 001 has been granted FDA orphan drug designation as a preventative therapy for cytokine release syndrome caused by bispecific antibody therapy.